A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates.
The current unprecedented outbreak of Ebola virus (EBOV) disease in West Africa has demonstrated the urgent need for a vaccine. Here, we describe the evaluation of an EBOV vaccine candidate based on Kunjin replicon virus-like particles (KUN VLPs) encoding EBOV glycoprotein with a D637L mutation (GP/D637L) in nonhuman primates. Four African green monkeys (Cercopithecus aethiops) were injected subcutaneously with a dose of 10(9) KUN VLPs per animal twice with an interval of 4 weeks, and animals were challenged 3 weeks later intramuscularly with 600 plaque-forming units of Zaire EBOV. Three animals were completely protected against EBOV challenge, while one vaccinated animal and the control animal died from infection. We suggest that KUN VLPs encoding GP/D637L represent a viable EBOV vaccine candidate.
State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
Oleg V
OV
Pyankov
State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
Sergey A
SA
Bodnev
State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia.
Olga G
OG
Pyankova
State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
Vladislav V
VV
Solodkyi
State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
Stepan A
SA
Pyankov
Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia.
Yin Xiang
YX
Setoh
Molecular Basis of Viral Pathogenicity, CIRI, INSERM, U1111-CNRS UMR5308, Université de Lyon, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, France.
Valentina A
VA
Volchkova
Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Andreas
A
Suhrbier
Molecular Basis of Viral Pathogenicity, CIRI, INSERM, U1111-CNRS UMR5308, Université de Lyon, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, France.
Viktor V
VV
Volchkov
State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
Alexander A
AA
Agafonov
Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia.
Alexander A
AA
Khromykh
D000354:Africa, Western; D000818:Animals; D002522:Chlorocebus aethiops; D046129:Ebola Vaccines / Q000276:immunology*; D029043:Ebolavirus / Q000276:immunology*; D006023:Glycoproteins / Q000276:immunology; D019142:Hemorrhagic Fever, Ebola / Q000276:immunology*; D007114:Immunization / Q000379:methods; D011323:Primates; D012093:Replicon / Q000276:immunology*; D058425:Vaccines, Virus-Like Particle / Q000276:immunology*; D014764:Viral Proteins / Q000276:immunology; D014902:West Nile virus / Q000276:immunology*
D046129:Ebola Vaccines; D006023:Glycoproteins; D058425:Vaccines, Virus-Like Particle; D014764:Viral Proteins
Ebola virus; Kunjin replicon; nonhuman primates; vaccine